All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @elldicken on TikTok · 12s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @elldicken's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Oh

@elldicken's 3 stone weight loss on Wegovy, fact-checked

Ellie | mama to 2 under 2

TikTok creator

61.1K viewsWatch on TikTok

Quick answer

Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg maintenance dose. Treatment requires ongoing use to maintain weight loss benefits.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @elldicken's 3 stone weight loss on Wegovy, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@elldicken's 3 stone weight loss on Wegovy, fact-checked" from Ellie | mama to 2 under 2. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying.

The reason this review is not generic is the source wording and the canonical claim label "glp1 3 stone down confidence up fyy wegovyjourney weightl." In this clip, the useful excerpt is: "Oh" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

3 stone (42 pounds) weight loss falls within expected ranges for Wegovy users
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg maintenance dose. Treatment requires ongoing use to maintain weight loss benefits.
  • The STEP 1 trial found 14.9% average weight loss with 2.4mg semaglutide over 68 weeks
  • 3 stone (42 pounds) weight loss falls within expected ranges for Wegovy users

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial found 14.9% average weight loss with 2.4mg semaglutide over 68 weeks
  • 3 stone (42 pounds) weight loss falls within expected ranges for Wegovy users
  • 44.2% of STEP 1 participants experienced nausea as a common side effect
  • Wegovy costs $1,200-1,400 monthly without insurance coverage
  • Weight regain typically occurs if treatment stops, with two-thirds of weight returning within a year
  • 32% of trial participants lost at least 20% of their body weight on maximum doses
  • Individual results vary significantly despite consistent dosing and adherence

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

@elldicken shares her weight loss transformation using Wegovy, claiming she's lost 3 stone (42 pounds) and gained confidence. The video shows before-and-after photos documenting her physical changes on the GLP-1 medication.

Her caption is refreshingly straightforward compared to many weight loss TikToks. She doesn't make wild promises about timeline or results everyone can expect. The focus stays on her personal experience rather than medical advice.

The hashtags suggest this is part of a broader "Wegovy journey" narrative that's become popular on social media platforms.

Is 3 stone of weight loss realistic on Wegovy?

Absolutely. The STEP 1 trial (Wilding et al., NEJM, 2021) found participants lost an average of 14.9% of their body weight over 68 weeks on 2.4mg semaglutide. For someone starting at 280 pounds, that's roughly 42 pounds.

The STEP 2 trial showed even higher losses in people with diabetes. At 68 weeks, participants on 2.4mg semaglutide lost 9.6% of body weight compared to 3.4% on placebo.

What @elldicken doesn't mention is timeline, which matters. Most people don't see maximum weight loss until month 16-20 of treatment. The medication works by slowing gastric emptying and reducing appetite through GLP-1 receptor activation in the brain.

What's missing from her story?

The video skips over Wegovy's side effects, which hit most users hard initially. The STEP 1 trial reported nausea in 44.2% of participants, vomiting in 24.8%, and diarrhea in 29.8%.

She also doesn't mention the cost reality. Wegovy runs about $1,200-1,400 monthly without insurance coverage. Many insurance plans still don't cover it for weight loss.

The confidence boost she mentions is real but incomplete. Weight regain typically happens if you stop the medication. The STEP 1 withdrawal study showed participants regained two-thirds of lost weight within a year of stopping treatment.

Should you trust transformation posts like this?

@elldicken's post is more honest than most weight loss content online. She doesn't promise quick fixes or claim everyone will get identical results. Her 3 stone loss falls within expected ranges from clinical trials.

But individual results vary wildly with GLP-1 medications. In STEP 1, 32% of participants lost at least 20% of their body weight, while others saw minimal changes despite staying on the full dose.

The real question isn't whether Wegovy works (it does), but whether you can access it consistently and afford long-term treatment. That's the part most transformation videos conveniently skip.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ellie | mama to 2 under 2 · TikTok creator

61.1K views on this video

3 stone down, confidence up 💃✨ #fyy #wegovyjourney #weightlosstransformation #weightlossglowup #f

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial found 14.9% average weight loss with?

The STEP 1 trial found 14.9% average weight loss with 2.4mg semaglutide over 68 weeks

What does the video say about 3 stone (42 pounds) weight loss falls within expected ranges?

3 stone (42 pounds) weight loss falls within expected ranges for Wegovy users

What does the video say about 44.2% of step 1 participants experienced nausea as a common?

44.2% of STEP 1 participants experienced nausea as a common side effect

What does the video say about wegovy costs $1,200-1,400 monthly without insurance coverage?

Wegovy costs $1,200-1,400 monthly without insurance coverage

What does the video say about weight regain typically occurs if treatment stops, with two-thirds of?

Weight regain typically occurs if treatment stops, with two-thirds of weight returning within a year

What does the video say about 32% of trial participants lost at least 20% of their?

32% of trial participants lost at least 20% of their body weight on maximum doses

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ellie | mama to 2 under 2, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.